Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» COPD
COPD
Trials to watch: Four biologics concluding pivotal COPD trials
Clinical Trials Arena
Thu, 07/25/24 - 11:36 am
COPD
biologics
clinical trials
GSK
Nucala
AstraZeneca
Fasenra
Roche
astegolimab
Sanofi
Regeneron
Dupixent
Sanofi and Regeneron's Dupixent scores in Europe as the first biologic to treat COPD
Fierce Pharma
Wed, 07/3/24 - 11:26 am
Sanofi
Regeneron
Europe
COPD
Dupixent
FDA approves Verona Pharma's inhaled COPD therapy
Reuters
Thu, 06/27/24 - 11:35 am
Verona Pharma
FDA
COPD
Ohtuvayre
Verona Gears Up for First Novel COPD Approval in Over a Decade
BioSpace
Tue, 06/25/24 - 11:12 am
Verona Pharma
COPD
ensifentrine
Dupixent nears EU approval for COPD, as FDA delays
Pharmaphorum
Fri, 05/31/24 - 10:49 am
Sanofi
Regeneron
Dupixent
COPD
EMA
Europe
FDA
Where competition is heating up in pharma
Pharma Voice
Fri, 05/24/24 - 11:06 am
competition
oncology
immunology
COPD
RSV
ulcerative colitis
GSK
JNJ
Moderna Therapeutics
AstraZeneca’s Fasenra asthma drug shows promise for COPD treatment
Biopharma Reporter
Tue, 05/21/24 - 11:27 am
AstraZeneca
COPD
Fasenra
clinical trials
Despite midstage trial miss, Amgen and AstraZeneca see promise for Tezspire in COPD
Fierce Pharma
Mon, 05/20/24 - 11:25 am
Amgen
AstraZeneca
COPD
Sanofi
Regeneron
Tezspire
Dupixent
Blackstone unearths Uniquity Bio with $300M to explore Merck drug's I&I potential
Fierce Biotech
Wed, 05/15/24 - 11:21 am
Blackstone Life Sciences
Uniquity Bio
solrikitug
COPD
asthma
Verona Secures Up To $650M in Funding as it Gears Up for Potential COPD Approval and Launch
BioSpace
Fri, 05/10/24 - 11:28 am
Verona Pharma
funding
COPD
Amgen Highlights New COPD, Asthma and Vasculitis Research at ATS 2024
BioSpace
Wed, 05/1/24 - 09:31 am
Amgen
Tezspire
COPD
AMG104
severe asthma
Tavneos
vasculitits
R&D
ATS
COPD Market Poised for ‘Paradigm Shift’ with Potential Approvals in 2024
BioSpace
Wed, 03/27/24 - 11:06 am
COPD
Sanofi
Regeneron
Verona Pharma
Dupixent
ensifentrine
After decades of waiting, late-stage therapies may penetrate the COPD market this year
Clinical Trials Arena
Sun, 03/24/24 - 10:31 pm
COPD
drug development
Sanofi
Regeneron
Dupixent
Verona
ensifentrine
GSK joins AstraZeneca, Boehringer in capping US out-of-pocket inhaler prices at $35 per month
Fierce Pharma
Thu, 03/21/24 - 06:37 pm
GSK
Boehringer Ingelheim
AstraZeneca
drug pricing
COPD
asthma
AstraZeneca follows rival Boehringer in capping out-of-pocket costs for inhalers
Reuters
Mon, 03/18/24 - 11:05 am
AstraZeneca
inhalers
drug pricing
Boehringer Ingelheim
Airsupra
Bevespi Aerosphere
Breztri Aerosphere
COPD
AstraZeneca kick-starts Phase III COPD trial for Breztri
Clinical Trials Arena
Thu, 03/14/24 - 11:21 am
AstraZeneca
COPD
clinical trials
Breztri
Boehringer to cap out-of-pocket inhaler cost at $35 per month
Reuters
Thu, 03/7/24 - 11:08 am
Boehringer Ingelheim
drug pricing
Atrovent
Combivent Respimat
Spiriva HandiHale
COPD
Sanofi, Regeneron Secure FDA Priority Review for Dupixent in COPD
BioSpace
Fri, 02/23/24 - 10:43 am
FDA
Sanofi
Regeneron
Dupixent
priority review
COPD
4 biotechs to watch in 2024
Pharma Voice
Wed, 02/21/24 - 11:28 am
biotech
IPOs
Alto Neuroscience
Verona Pharma
Karuna Therapeutics
Madrigal Pharmaceuticals
precision medicine
COPD
Alzheimer's disease
NASH
Beleaguered Theravance logs head-to-head trial loss for Yupelri against Boehringer's Spiriva
Fierce Pharma
Sun, 01/7/24 - 04:07 pm
Theravance
Yupelri
COPD
Boehringer Ingelheim
Spiriva
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »